Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly ...

Crinetics Pharmaceuticals, Inc.: Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Adults with Acromegaly

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...
AHA/ASA Journals

Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults

BACKGROUND: Early detection of atrial fibrillation (AF) is essential for preventing ischemic stroke and other cardiovascular complications. However, the incidence and prognosis of AF in the general ...